ARTICLE | Clinical News
Arbaclofen placarbil: Completed Phase IIb enrollment
November 15, 2010 8:00 AM UTC
XenoPort disclosed in its 3Q10 earnings that it completed enrollment of 425 patients in a double-blind, placebo-controlled, North American Phase IIb trial evaluating arbaclofen placarbil at doses of 2...